Teva Pharmaceutical Industries Limited (TEVA) PT Set at $10.00 by Cantor Fitzgerald

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been assigned a $10.00 target price by analysts at Cantor Fitzgerald in a report issued on Tuesday. The brokerage currently has a “hold” rating on the stock. Cantor Fitzgerald’s price target points to a potential downside of 20.63% from the stock’s previous close.

A number of other brokerages have also weighed in on TEVA. Jefferies Group LLC reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday, July 25th. Vetr raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 target price on the stock in a research note on Monday, July 24th. Zacks Investment Research raised shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $37.00 target price (down previously from $38.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, July 17th. Finally, Mizuho reaffirmed a “hold” rating and set a $30.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 2nd. Seven research analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $21.99.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded up $0.85 on Tuesday, hitting $12.60. 34,875,400 shares of the stock were exchanged, compared to its average volume of 15,254,189. The company has a market cap of $12,030.00, a price-to-earnings ratio of 2.71 and a beta of 0.52. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries Limited has a 52-week low of $10.85 and a 52-week high of $39.41.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/16/teva-pharmaceutical-industries-limited-teva-pt-set-at-10-00-by-cantor-fitzgerald.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in TEVA. Capital Research Global Investors grew its position in Teva Pharmaceutical Industries Limited by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after buying an additional 9,260,426 shares during the period. Franklin Resources Inc. boosted its position in shares of Teva Pharmaceutical Industries Limited by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after purchasing an additional 6,685,844 shares during the period. FMR LLC boosted its position in shares of Teva Pharmaceutical Industries Limited by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after purchasing an additional 6,115,853 shares during the period. Macquarie Group Ltd. boosted its position in shares of Teva Pharmaceutical Industries Limited by 350.3% in the third quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock worth $77,587,000 after purchasing an additional 3,429,448 shares during the period. Finally, Capital World Investors boosted its position in shares of Teva Pharmaceutical Industries Limited by 41.9% in the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock worth $367,686,000 after purchasing an additional 3,268,200 shares during the period. Institutional investors own 55.81% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply